1. Introduction {#s0005}
===============

A wide variety of vegetables, fruits, spices and herbs have been consumed since distant past for a number of applications, including disease preventive and therapeutic, and are known to contain various bioactive compounds. Mother nature has bestowed mankind with a huge sum of contemporary therapeutic resources since the distant past. Plants are the natural source of many of the phytoconstituents as contemporary drugs which have found their place in modern therapeutics ([@b0250]). Of all the medical prescriptions today in developed countries like the US, almost 25--30% compounds are from the plant origin, which are employed for the treatment of various ailments in the contemporary practice of medicine. While in developing countries like India and China this data may reach to as much as 80%. Present estimation of world market of drugs obtained from plant sources may lie somewhere near 30,000 million USD ([@b0415]). (See [Table 1](#t0005){ref-type="table"})Table 1^13^C and ^1^H NMR spectra of thymoquinone in CDCl~3.~DesignationType of carbon atom^1^H NMR signal δ \[ppm\], *J* \[Hz\]^13^C NMR signal δ \[ppm\]C-1Cq--188.6C-2Cq--145.2C-3CH6.59\
J = 1.58133.8C-4Cq--187.4C-5Cq--155.0C-6CH6.52\
J = 1.18130.4C-7CH~3~2.05\
J = 1.5815.4C-8CH3.03\
J = 6.94, 1.1826.5C-9/10CH~3~1.13\
J = 6.9421.4

The plants which possess medicinal properties have always proven their worth and vitality for the benefits of mankind. Plants possess a vast assortment of exuberant and eternal resources of bioactive constituents which are applied for the treatment of numerous diseases. Some of the vital and eminent bioactive constituents of plants include alkaloids, glycosides, tannins, flavonoids, phenolic compounds, resins, lectins, etoposides, tanniposides, fatty acids, waxes, terpenoids, phenolic acids and polypropanoids, etc., ([@b0470], [@b0015], [@b0020]). These bioactive constituents exhibit a wide array of medicinal and pharmacological activities like anti-tubercular, anti-cancer, anticoagulant, immunomodulatory, aldehyde oxidase inhibitors, anti-oxidant, antidiabetic, anti-inflammatory, influenza virus neuraminidase inhibitors, antibacterial, antifungal, antiplatelet, anti-degranulating, anti-trypanosomal activities ([@b0405], [@b0120]).

Among these, *Nigella sativa L.* is one of the promising plant sources to a range of bioactive constituents like Thymoquinone, α-pinene, p-cymene, monoterpenes etc. *Nigella sativa L.* and its seeds are known by a number of other names like *Nigella sativa L*., black cumin, black caraway, nutmeg flower, fennel flower, Roman coriander and kalonji ([@b0445]).

Thymoquinone (2-Isopropyl-5-methyl-1, 4-benzoquinone) is the bioactive constituent of the volatile oil of black cumin (*Nigella sativa L.)* seeds that has been extensively utilised traditionally in Middle East and Southeast Asian countries owing to its various health promoting capacities ([@b0315]). It has been widely analyzed for its broad range of medicinal and pharmacological activities including but not limited to anti-inflammatory ([@b0480]), anti-oxidant ([@b0075]), antihistaminic ([@b0235]), antitumor ([@b0450]), analgesic ([@b0065]), anti-Alzheimer's ([@b0130]), hepatoprotective, neuroprotective ([@b0345]), renoprotective, histone protein modulator ([@b0400]), insecticidal ([@b0425]), anti-ischemic ([@b0125]), Leishmanicidal ([@b0310]), radioprotective effects ([@b0035]). TQ has also been clinically tested for a diverse kind of ailments like arthritis, diabetes, hypercholesterolemia etc. and is known for its eminent activity against a range of human carcinomas as it has negligible toxicity against normal cells. A number of studies have revealed the exploration of different molecular pathways for different cellular mechanisms for the therapeutic potentiality of TQ in the management of different types of metastatic tumors ([@b0105]). Multiple molecular targets are acted upon by TQ through different pathways, and also it shows its actions via many cellular mechanisms like proliferation inhibition, induction of apoptosis, cell cycle interruption, reactive oxygen species (ROS) production, and prevention of angiogenesis and cellular metastasis.

2. Chemistry {#s0010}
============

TQ is a non-toxic major bioactive compound obtained from the oil of black seeds of *Nigella sativa L.*, has a chemical structure as shown in [Fig. 2](#f0010){ref-type="fig"}, and bears the chemical formula C~10~H~12~O~2~ and molecular weight of 164.204 g/mol. The concentration of TQ in the seed oil has been reported to be between 18 and 25 µg/mL. TQ exhibits important properties such as antimicrobial, analgesic and anti-inflammatory, protecting organs against oxidative damage, induced by an array of free radical producing agents, neuromodulatory, inhibition of eicosanoid generation and membrane lipid peroxidation, providing it the sufficient attraction for modern pharmacology ([@b0170]). In TGA analysis the thermal decomposition of TQ starts at 65 °C and finishes at ∼213 °C. Alkharfy et al.; report that TQ belongs to the monoterpenes class of natural compounds ([Fig. 1](#f0005){ref-type="fig"}) and has been reported to be showing keto-enol tautomerism. Specifically, TQ is a tautomeric compound where keto-form is the major configuration which exhibits pharmacological actions ([@b0015], [@b0020]). TQ is a 10 carbon compound having a basic quinone ring moiety of 6 carbons while the 7th methyl group carbon at position C2 and 8th, 9th and 10th propyl group at position C5. Two of the most frequently synthesized close derivatives of TQ are dithymoquinone and thymohydroquinone **(**[Fig. 3](#f0015){ref-type="fig"}**)**. Thymoquinone closely resembles basic monoterpene skeletal moiety with 10 carbon structure having the basic molecular formula C~6~H~16~ and composed of two isoprene units containing a ring **(**[Fig. 1](#f0005){ref-type="fig"}**)** having significant relevance to pharmaceutical, cosmetic, agricultural and food industries. High resolution powder x-ray diffraction (PXRD) and simulated annealing based molecular location method shows a triclinic unit cell with a = 6.73728(8) Å, b = 6.91560(8) Å, c = 10.4988(2) Å, α = 88.864(2)°, β = 82.449(1)°, γ = 77.0299(9)°; cell volume = 472.52(1) Å^3^, Z = 2. The UV--Visible absorption spectra of TQ shows the absorption maxima at λ~max~ of 257 nm in physiological phosphate buffered saline pH 7.4, ([@b0265]) while its spectra in ethanol exhibits a π → π\* transition spectra with a maxima at 252 nm with an extinction coefficient of 25000 cm^2^ × mmol^−1^ ([@b0435]). The FTIR spectrum of TQ establishes the presence of a carbonyl within a conjugate system by two specific bands at 1669 and 1621 cm^−1^ (because of Fermi resonance) and C-H strong stretching of aliphatic groups which are specific features in such p-benzoquinones, the weaker bands at higher wavenumber 3040 cm^−1^ represent the stretching observed in vinyl C-H in the C = C-H groups ([@b0060]).Fig. 1Basic chemical structure and atom numbering of monoterpene skeleton.Fig. 2The chemical structure and atom numbering for Thymoquinone.Fig. 3The chemical structure of close derivatives of thymoquinone.

2.1. Structural chemistry of thymoquinone {#s0015}
-----------------------------------------

TQ is a 10 carbon compound having the IUPAC name 2-isopropyl-5methyl-1,4-benzoquinone. It is a solid bright yellow compound having scaly crystals with a melting point of 49--50 °C and gives a characteristic intense smell of pepper. The solubility of TQ varies in the range of 549--669 µg/mL in all aqueous solutions ([@b0015], [@b0020]). TQ is unstable in aqueous solutions particularly at alkaline pH and also possess severe light sensitivity. It contains two carbon--carbon double bonds (C000000000000 000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000 000000000000C) and two carbon-oxygen double bonds (CO). It possesses 0 hydrogen bond donor count, while hydrogen bond acceptor count is 2 and a rotatable bond count of 1 with the logP value of 2. The topological polar surface area of TQ is 34.1 A^2^ ([@b0060]).

The NMR spectrum of TQ elucidates as, at δ~H~ = 1.13 gives the doublet for methyl groups 9 and 10 along with *J* = 6.94 Hz. Consequently, a singlet of methyl group for proton number 7 at δ~H~ = 2.04. The signal from the methine proton at eighth position of the isopropyl group comes as a septet. It exhibits an extra pairing with 6th proton of 1.18 Hz. The second one repeats in the olefinic doublet at δ~H~ = 6.52 that has to be attributed to 6th proton. 3rd proton at δ~H~ = 6.59 is shown as a quadruplet because of the pairing with the CH~3~ group 7th proton. The concept, that 6th proton is more protected than 3rd proton is because of the plus inductive effect (+I-effect) of the isopropyl functionality ([@b0435]).

The electro-ionization stimulated atomization of TQ is controlled by decarbonylation step and CH~3~-elimination, which in separate episodes tends to the most vivid ion having formula C~7~H~9~^+^ (*m*/*z* 93). The range of unsubstituted 1,4-benzoquinone is controlled by the voiding of ethyne from the molecular ionic part. If this was being employed to TQ, it would further extends to the exit of propyne group and 3-methylbutyne to impart C~7~H~6~O~2~^+^. *m*/*z* 124 and C~5~H~4~O~2~^+^. *m*/*z* 96, but, this does not happen. Any ionic part with *m*/*z* 124 cannot be detected and the ionic part with *m*/*z* 96 as per the determination of mass at high resolution has the constitution C~6~H~8~O^+^.... It is shaped after the first decarbonylation maneuver by the disintegration of the ionic part with mass by charge ratio of 136. However, if rather than that propyne, 3-methylbutyne is annihilated as a neutral part, then the similar C~4~H~4~O^+.^ (*m*/*z* 68) is received. Successive decarbonylation results from *m*/*z* 68 or respectively 96 to the ionized part of alkynes C~3~H~4~^+^. (*m*/*z* 40) or respectively C~5~H~8~^+^. (M/z 68). The contribution of C~5~H~8~^+^. To the total intensity at *m*/*z* 68, which majorly comes from C~4~H~4~O^+^, is small ([@b0435]).

2.2. Biosynthesis of thymoquinone {#s0020}
---------------------------------

TQ obtained from *Nigella sativa L.* (Black Cumin), an annual herb frequently used in Middle Eastern countries and India has been gaining a worldwide acceptance presently. An extensive range of historical traditional and medicinal uses have been documented in the text. TQ is a secondary metabolite biosynthesized by plants mainly by terpene biosynthetic pathway. A striking similarity exists in the structures of different monoterpene components of *Nigella sativa L.* volatile oil and their presence in the species that accumulate similar compounds.

TQ belongs to the class of monoterpene compounds which are formally descended by condensation of two isoprene units. The secondary metabolism in plants predominantly leads to the formation of these, which can be isolated by steam distillation or solvent extraction of plant parts. The universally accepted "biogenic isoprene rule" generalizes that naturally occurring terpenoids are derived from either directly or by predictable stereospecific cyclization, rearrangement and dimerization from acyclic C-10 precursors like geraniol.

Geranyl diphosphate undergoes cyclization and forms γ-terpinene, which in turn is aromatized into *p-*cymene and then it is followed by hydroxylation to carvacrol. Further hydroxylation of carvacrol takes place and leads to the formation of thymohydroquinone. Thymohydroquinone undergoes oxidation and finally leads to the formation of TQ **(**[Fig. 4](#f0020){ref-type="fig"}**)**. In some species and chemotypes which accumulate thymol in place of carvacrol, an alternate biosynthetic pathway occurs, where hydroxylation of *p-*cymene to thymol takes place. Monoterpene composition generally alters during the maturation of seeds. In immature seeds the major monoterpenes are γ-Terpinene and α-thujene and the former is slowly substituted by *p*-cymene, carvacrol, thymohydroquinone, and TQ as the seed development occurs. Zawirska Wojtasiak *et al*.; isolated a number of compounds from *Nigella sativa L.* essential oil and separated six pairs of enantiomers. They reported that the main odorant of *Nigella sativa L.* --thymoquinone and p-cymene -- are not chiral ([@b0530]).Fig. 4A schematic diagram for the biosynthesis pathway of thymoquinone.

3. Source and occurrence of thymoquinone {#s0025}
========================================

TQ is a naturally occurring quinone derivative, commonly called black caraway seed or black cumin obtained from *Nigella sativa L.* of family Ranunculaceae. *Nigella sativa L.* is a flowering plant which is found in countries adjoining Mediterranean sea, India, Pakistan, and Iran. The plant has a varying composition of many constituents like fixed oils, volatile oils, alkaloids, saponins, coumarins, minerals, fibers etc ([@b0320]). *Nigella sativa L.* contains the bioactive compound TQ which constitutes like 54% of the volatile oil in the annual herbal flowering plant. Traditionally it has been used as a spice, but also as a medicine. Certain essential fatty acids are also present in the triglycerides of oil but TQ is the main constituent ([@b0350]). Thymoquinone is obtained as a result of the oxidation of thymol, which is also a natural product, in the presence of manganese oxide in acidic medium to thymol. The quantity of essential oil in the oil of black seed varies between 0.5 and 1% and approximately one-third of it is TQ which gives yellow color to the black seed oil ([@b0245]). TQ is also reported in other plants such as *Nepeta Leucophylla, Tetraclinis articulata, Juniperus Cedrus, Callitris quadrivalvis, Monarda fistulosa* etc. It has also been reported in genus *Tetraclinis, Cupressus,* and *Juniperus* of the Cupressaceae family ([@b0195]).

Besides Ranunculaceae, where only minute quantities of TQ are found, its presence has also been confirmed in other genera of Laminaceae family like *Agastache, Coridothymus, Monarda, Mosla, Origanum, Satureja, Thymbra,* and *Thymus* ([@b0195])*.* In plants, TQ is found along with its dimeric and reduced forms dithymoquinone and thymohydroquinone, the latter being a compound with significant biological activities ([@b0205]). Similar to TQ, THQ is found in a number of genera of the family like *Coridothymus, Origanum, Monarda, Mosla, Satureja,* and *Thymus* ([@b0475])*.*

4. Bioavailability, safety and toxicity {#s0030}
=======================================

The rate and extent of a drug which reaches the systemic circulation from the site of administration is known as bioavailability of that particular drug. It is the major factor to be considered for good therapeutic efficacy of the drug ([@b0115]). Among various physicochemical parameters which affect the bioavailability of drug or its dosage form, solubility is one of the major parameter that plays a crucial role to determine the bioavailability of any drug moiety. To enhance the bioavailability and efficacy of TQ people are trying various nanoformulations, i.e., liposomes, solid lipid nanoparticles (SLNs), niosomes, nanostructured lipid carriers (NLCs), nanoemulsions etc. When self nanoemulsifying drug delivery system of TQ was prepared, its bioavailability has been increased 3.87 fold in comparison to TQ suspension ([@b0485], [@b0465], [@b0175], [@b0230]). The bioavailability of TQ has been reported to get enhanced 5 times by SLN preparation in comparison to conventional formulations when tested on albino wistar rats ([@b0440]). In an *in vivo* study performed on albino Wistar rats TQ shows enhanced bioavailability in NLC formulation when compared to suspension by 3.97 fold with increased plasma half-life ([@b0160]).

Toxicity studies have immense importance in the safety assessment of new compound before these get tested in human trials. In this regard, the toxic effects of the drug on laboratory animals have been tested and then the similar effect has been assessed on human individuals. The LD~50~ (lethal dose) of TQ is dependent on route of administration and vehicle used because of its insoluble nature in water. It also varies based on the type of rodent, i.e., mice and rats mainly. The LD50 of TQ on oral administration in mice was 870.9 mg/kg and after i.p. (intraperitoneal) injection, it became 104.7 mg/kg. The same has been reported in rats as 794.3 mg/kg and 57.5 mg/kg after oral and i.p. administration respectively ([@b0485], [@b0040], [@b0010]). The toxicity signs after oral administration of TQ reported are difficulty in respiration (dyspnoea) and peritonitis after i.p. injection in rats and mice ([@b0005]). However, it is also reported that on long term administration of TQ alone or TQ-NLC causes liver toxicity but at the tolerable dose, it does not affects the organ function. They authors also concluded that the NLC formation of TQ increased the tolerability of TQ alone in their experiment upto 100 mg/kg ([@b0005], [@b0350]).

5. Thymoquinone and inflammation {#s0035}
================================

Inflammation is the first line of body defense mechanism from noxious external stimuli. The ultimate purpose of this reaction is to protect the organism from the initial injury and then the result of it. When these inflammatory reactions are not controlled by natural physiological processes then it may cause inflammatory diseases which are commonly spread over worldwide. For the treatment of these diseases, there are two categories of drugs are used, i.e., steroidal anti-inflammatory drugs and non-steroidal anti-inflammatory drugs (NSAIDs). Steroidal drugs are proven potent for inflammatory diseases but prolonged use may impact serious adverse effects. On the other hand prolonged use of NSAIDs also leads to side effects ([@b0070]).

Due to the above mentioned troubles associated with these synthetic drugs, there is a strong need for research on natural products which are justified as safer. TQ is one of the principle constituent of *Nigella sativa L.,* a herb which is used in the traditional system of Indian medicines for the treatment of various systems of inflammatory conditions. TQ is reported to inhibit eicosanoids productions mainly thromboxane B and leukotrienes B4 by affecting the level of COX and LOX respectively. These enzymes are the main factor in the inflammatory pathway and act by expressing different inflammatory cytokines which cause oxidative stress and infiltration of neutrophils and macrophages and finally lead to tissue damage. TQ has a role in inhibition of nitric oxide production by macrophages which proves its anti-inflammatory action ([@b0360], [@b0380]). Reports also suggested that it has an activity to preserve the action of antioxidant enzymes such as catalase, glutathione peroxidase, and glutathione-S-transferase and acts as free radical as well as superoxide radical scavenger ([@b0220]). There are numerous cytokines such as TNF-α, IL-1, IL-2, IL-6, and IL-10 which have a considerable role in inflammation. Among these TNF-α and IL-1 is important for the overexpression of other pro-inflammatory cytokines (IL-6 and IL-8), reactive oxygen/nitrogen species (ROS/RNS) and lipid mediators which may cause organ failure while sepsis. The level of these cytokines is modulated in sepsis when treated with TQ. Apart from this NF-κB also play an important role in sepsis by upsurging the level of proinflammatory cytokines. TQ also has an inhibitory effect on NF-κB during sepsis such that it inhibits the production of proinflammatory cytokines thereby decreasing the infiltration of inflammatory cells and showed protective action against tissue and organ damage ([@b0050]).

Oxidative stress in systemic inflammation has also been reported with a critical role in memory and learning impairment. Studies also suggested that neuro-inflammation induced by lipopolysaccharide (LPS) causes impairment of learning and memory through release of pro-inflammatory cytokines and over production of ROS. In a mouse model, learning and memory impairment induced by LPS was associated with an increased level of TNF-α and IL-6 in hippocampal and IL-6 in cortical tissue. Administration of TQ is associated with a reduction of hippocampal TNF-α and IL-6 levels and also TQ exhibited its anti-inflammatory activity via suppressing NF-κB and inhibition of cytokine production. In this study authors explained that the neuroprotective effects of TQ are expressed in terms of the improvement in learning and memory in the LPS induced model has occurred ([@b0100]).

6. Thymoquinone and angiogenesis {#s0040}
================================

The formation of new blood vessels or the development of blood vessels is known as angiogenesis. More strictly it is also known as the development of blood vessels from pre-existing vessels ([@b0385]). It is controlled by some factors such as fibroblast growth factors (FGFa and FGFb), transforming growth factor (TGF-α and TGF-β), hepatocyte growth factor (HGF), tumor necrosis factor (TNF-α), angiogenin, interleukin-8, and angiopoietins. Among all these, one of the most important factors that contributes to angiogenesis is vascular endothelial growth factor (VEGF). In *in-vitro* condition VEGF stimulates the endothelial cell growth which is mainly originated from veins, arteries and lymph drainage vessels. It is an endurance mechanism for the endothelial origin cells in vitro as well as *in vivo* circumstances ([@b0240]).

TQ treatment significantly decreases angiogenesis via regulating the signal of VEGF through Akt and extracellular receptor kinases pathway ([@b0325]) ([@b0375]). TQ reduces the tumor blood vessels in human prostate cancer (PC3)^53^ and osteosarcoma (SaOS-2) cells xenograft model in nude mice. In osteosarcoma it suppresses the angiogenesis markers VEGF and CD34. In the same research it is also demonstrated that it affects the angiogenesis by acting on NF-κB. Some reports are also available for antiangiogenic activity of TQ with the same VEGF mechanistic activity in different cell lines ([@b0375], [@b0365], [@b0285], [@b0155], [@b0355]). Inhibition of VEGF not only directly inhibits the angiogenesis but also it causes the necrosis in that particular area of tumor development and in this way it may hamper the blood vessel formation ([@b0025]). This effect was observed in the combination treatment of TQ with resveratrol ([@b0055]).

In 2008 Tingfang Yi et al. Reported that thymoquinone hinders with the angiogenesis which is a vital manoeuvre in tumor growth and metastasis. They explained that TQ downregulated the AKT activation and extracellular signal-regulated kinase and inhibits angiogenesis *in-vitro* and *in-vivo*. It also stops the tumor angiogenesis in xenograft human prostate cancer (PC3) mice model ([@b0525]). Another report by Woo et al. reports that TQ exerts its anti-tumor effects via diverse mechanisms including the inhibition of angiogenesis, and through a number of molecular targets like p53, p73, STAT3 and PPAR-ϒ etc. Co-administration of TQ with Tamoxifen was assessed for its anti-angiogenic potential via regulation of a number of molecular signalling targets viz. Akt, XIAP, PI3-K-AKT, PARP etc. and was reported to cause tumor necrosis and tumor growth arrest through angiogenesis inhibition in MCF-7 breast tumor xenograft ([@b0510]).

In 2010, Banerjee et al., reviewed the molecular and therapeutic potential of thymoquinone in cancer and explained the anti-inflammatory and anti-tumor potential of thymoquinone. They suggested that TQ inhibits tumor cell proliferation via regulation of apoptosis signalling, angiogenesis inhibition and arresting of cell cycle ([@b0095]). Another report suggests that TQ activates the tumor suppressor genes and also inhibits angiogenesis process by activation of some significant motifs of angiogenesis ([@b0255]).

TQ also inhibits endothelial cell migration and as seen in the HUVEC cell migration inhibition in a dose dependent manner. The authors also report that suppression of VEGF production and thus prevention of tumor growth through anti-tumor angiogenesis by TQ is justified by the significantly decreased serum concentration of VEGF in TQ treated group compared to normal control. TQ also exerts its anti-angiogenesis effects via NF-κB pathway and its downstream molecules, by inhibition of HUVEC differentiation into tube like structure, decreasing the tube formation capacity by endothelial cells. TQ exerts its effects on COX2 expression and prostaglandins production in mouse model, and overexpression of COX2 has a significant part in the angiogenesis upregulation ([@b0410]). The effect of TQ on angiogenesis was studied by CD31 immunostaining in lung cancer xenograft in nude mice, where the authors report that the antitumor effects of thymoquinone are due to the anti-apototic effects and not because of the anti-angiogenesis effects as no significant neoangiogenesis was observed between the TQ treated group and control LNM35 tumor xenograft ([@b0080]).

7. Thymoquinone and apoptosis {#s0045}
=============================

Apoptosis is programmed cell death in response to pathological or physiological changes which are directed to eliminate the dead, mutated or aged cell. In other words, it can be said that it is the cleaning pathway of a biological system from dead cells that may cause a potential health threat to the body if not removed. There are two main pathways of apoptosis - first, intrinsic pathway/mitochondrial pathway which is regulated by Bcl protein family. In this pathway initially, various stimuli trigger the increment of mitochondrial membrane permeability and finally releases apoptogenic factors that cause the membrane disruption and mitochondrial dysfunction. This dysfunction activates various apoptogenic proteases, e.g., caspases. Second, these caspases are also activated by the formation of a death receptor at the cellular surface ([@b0090]). Drugs acting on either pathway of apoptosis are currently focused on anticancer therapy. For example activities of caspases like caspase-3, caspase-9 or cleaved caspase -3 are studied as hall marks of apoptosis in cancer cells ([@b0180], [@b0185]). Treatment of TQ in spinal cord injury reduces the activity of caspase-3 and caspase-9 and inhibited apoptosis in an animal model ([@b0140]) and the same mechanism has also been reported in gastric carcinoma ([@b0165]).

Also cell may undergo DNA damage which may be repairable or irrepairable which implies that either DNA damage is repaired correctly or may be rendered as irrepairable ([@b0180], [@b0185]). When cells undergo DNA damage and if it is unrepairable then apoptosis may occur which is attributed through the treatment of TQ on glioblastoma cell. In the same study author conclude that TQ induced apoptosis via the elevated level of Bax and cytochrome *c* proteins. They have also shown that TQ induces apoptosis through p^53^ independent pathway ([@b0190]). In contrast to that, the authors also reported that p^53^ dependent pathway may also get involved in apoptosis. Although in this study they reported that the apoptosis induced by TQ was concentration dependent which involves p^53^ elevation as well as down regulation of Bcl-2. Multiple pathways are reported for the induction of apoptosis by TQ treatment which are Jak-STAT, Akt, Notch, ERK-JNK, and NF-κB. In bladder cancer cell lines TQ induces apoptosis through endoplasmic reticulum mediated mitochondrial pathway in which increased ratio of Bax/Bcl-2 as well as cytochrome-c was found ([@b0535]). In another study, performed in the prostate cancer cell line (DU-145) the apoptotic activity of TQ has been reported and was due to ROS mediation. In the same study, TQ also showed synergistic activity in combination with zoledronic acid ([@b0150]). It showed the apoptotic effect in breast cancer cell line (T47D) in combination with gemcitabine as well as alone ([@b0110]).

8. Thymoquinone and cell cycle regulation {#s0050}
=========================================

The cell cycle of eukaryotes is divided into two major event DNA replication (S-phase) and mitosis (M-phase) with G1 and G2 gap events. All events are correlated in such a way to ensure the sequential regeneration of cell cycle events, and all these events are conserved throughout eukaryotes. In all eukaryotes, cyclin-dependent kinase (CDK) plays a crucial role and is highly conserved molecules responsible in the cell cycle ([@b0430]). CDK controls both cell cycle transition event as G1/S transition and G2/M transition. In yeast CDK encoded by CDC28 and mutation blocked the cell cycle progression at G1-phase by which cells enters in the sexual cycle instead of the mitotic cycle **(**[Fig. 5](#f0025){ref-type="fig"}**)**. CDKs require positive regulatory partners for activity, termed as cyclins and identified as proteins that fluctuate in bulk via cell cycle in progressive cleaving of early embryonic cells.Fig. 5Role of thymoquinone in cell cycle regulation.

Cyclin-dependent kinase resides a serine/threonine-specific catalytic core with regulatory subunits as cyclins, controls kinase activity, and substrate specificity. The first evidence of the role of Cdk/cyclin complex in cell cycle control was noted in yeast. Further evidence was found by researchers that Cdk responsible for cell cycle progression and cyclins manages the transition between cell cycle phases ([@b0305]). In every tumor cells the machinery that controls the process of cells to forward from resting to cell cycle are found altered ([@b0295]).

Thymoquinone downregulates interleukin-6 downstream inducible STAT3 stimulation in multiple melanoma cells in humans along with the supressing the c-Src and JAK2 stimulation including appearance of STAT3 regulated genetic consequences, like-cyclin D1, Bcl-2, Bcl-xL, surviving, Mcl-1, and VEGF. It has also been reported to inhibit the proliferation, accumulation of cancer cells in the sub-G1 phase and apoptotic phase ([@b0295]).

TQ potentiates natural killer cells activity and showed potent toxicity in WEHI-3 cell line, seen as the increment of early apoptosis, upregulation of anti-apoptotic protein, Bcl2, and downregulates the apoptotic protein, Bax. In the experiment, where both treated and untreated cells were analyzed for cell cycle distribution, it confirmed that TQ promotes decrement in the S-phase cells. The significant increment in the apoptosis is seen at 24 and 48 hr of treatment, confirms S-phase arrest in a time-dependent manner ([@b0420]).

Antineoplastic activity of TQ was observed against multifarious tumors. DNA concentrations in thymoquinone treated T47D and MDA-MB-468 cells were evaluated for cell cycle distribution. Cell cycle arrest at the G1 phase was observed within 12 and 24 hr incubation. Whereas 25% increment in the first G1 cell cycle phase was found in all types of breast cancer cells within 24 hr treatment with TQ followed by changing of G1 cell phase halt to sub G1 cell cycle phase towards apoptotic cell death within 48 hr treatment ([@b0390], [@b0395]).

TQ effect on cell proliferation, apoptosis and signalling pathways in HCT116 and HCT116**^p53-/-^** colon cancer and HepG2 hepatoma cells in vitro was observed by Wirries et al. and they found that HCT116 cells were most sensitive towards TQ treatment (10 uM) induces shifting of cell cycle distribution in S/G2 phase after 72 and 96 hr treatment. The increment of 67.8 to 89.1% and from 62.4 to 88.6% after 72 or 96 hr incubation with TQ ([@b0495]).

9. Thymoquinone and proliferation/invasion/ migration {#s0055}
=====================================================

The effect of TQ on the expression of eukaryotic elongation factor-2 kinase (eEF-2K) was explored in search for the new molecular target in Triple negative breast cancer (TNBC). The study revealed that TQ inhibits cell proliferation, migration/invasion and tumor growth in TNBC via NF-kB/miR-603/eFF-2K signalling axis, eEF-2K promotes tumor growth and progression by modulating the activity of Src, FAK, PI3K/Akt, c-Myc and cyclinD1 ([@b0225]).

TQ potential was evaluated on SiHa and CaSki cervical cancer cell lines in the modulation of epithelial to mesenchymal transition (EMT)-regulated proteins and cancer metastasis. TQ showed time-dependent and dose-dependent cytotoxic effect and restricts migration and invasion of cervical cancer cells. TQ restricts the expression of Twist1, Zeb1 expression and upregulates E-Cadherin expression and this inhibition strongly suggests that TQ directly targets the Twist1 and Zeb1. The decrement in the activity of Twist1 and Zeb1 promotes assertions that TQ might be the main target of TQ. So, TQ inhibitory effects in metastasis of cervical cancer cells are directly caused by Twist1/E-Cadherin/EMT or/and Zeb1/E-Cadherin/EMT signalling pathway ([@b0300]).

TQ effect was evaluated on cell proliferation, migration, invasion and anti-metastatic effect in lung cancer cell line A549 cells. Wound healing assay suggests dose-dependent increase in the inhibition of cell migration after 24, 48 or 72 hr in A549 cells. At 40 µM/L for 24, 48 or 72 hr as compared with negative control, cell migration inhibition follows time-dependent increase in A549 cells. Transwell invasion assay suggests dose-dependent increase in cellular invasion inhibition rate as compared to negative control after 24, 48 or 72 hr in A549 cells. Similarly at 20 µM/L dose of TQ shows time-dependent increment in inhibition of invasion after 24, 48 or 72 hr in A549 cells ([@b0520]).

Synergistic effect of TQ and temozolomide (TMZ) was observed in human glioblastoma multiforme cell line (U87MG). The TMZ is an alkylating agent and develops resistance in the treatment of cancer. Combination of TMZ and TQ showed the synergistic effect and inhibit 77% cell migration restricts the invasion of cancer cells by 43% leading to restrict the proliferation of cells in a time and dose-dependent fashion and inhibit the expression of MMP-2 and MMP-9 required for glioma malignancy ([@b0370]).

TQ restricts the expression of AKT and extracellular signal-regulated kinase signalling pathway leading to the inhibition of angiogenesis and development of the tumor. The study was performed in human umbilical vein endothelial cell for justifying the role of TQ in migration, invasion and tube formation properties of these endothelial cells. The results indicated that, these endothelial cells exhibited inhibition of proliferation and restrict the activation of AKT and extracellular signal-regulated kinase. In a wound-healing assay performed in HUVEC cells, it was found that TQ inhibits HUVEC migration in a concentration-dependent manner and in transwell invasion assay TQ significantly restricts invasion of cells at 80--100 nM/L. TQ efficiently suppresses the activation of VEGF-induced ERK and AKT excluding inhibition of VEGFR2 **(**[Fig. 6](#f0030){ref-type="fig"}**)**. Both AKT and ERK play a critical role in mediating cellular proliferation, survival and migration and TQ efficiently inhibits the activation of both AKT and ERK in endothelial cells ([@b0525]).Fig. 6Inhibition of VEGF receptors by thymoquinone leading to the downregulation of tumor metastasis.

Another study performed in renal cell carcinoma for determining the efficacy of thymoquinone on the migration and invasion of cancer cell, confirmed the inhibition of migrating and invasive ability of human RCC 769-P and 786-O cell lines. Results showed that TQ potentiates E-cadherin expression and downregulates the mRNA and protein level expression of Snail, ZEB1 and vimentin in a dose-dependent fashion. It also upregulates the phosphorylation levels of liver kinase B1 (LKB1) and AMP-activated protein kinase (AMPK). TQ showed nonsignificant changes in normal renal tubular epithelial HK2 cell line upon 24 hr; however slight decrement in the growth observed after 48 and 72 hr suggests low cytotoxicity over normal epithelial cells but concentration-dependent effect of TQ was observed over renal cell carcinoma cells in proliferation and migration of cancer cells. The migration of 769-P and 786-O cells significantly diminished and treatment of TQ with 10 uM for 24 hr significantly reduced the invasiveness of 769-P and 786-O cells. LKB1/AMPK signalling is required for the cancer metastasis and a concentration-dependent TQ treatment increases the phosphorylation level of both LKB1 and AMPK upon in both the cancer cell lines ([@b0280]).

10. Thymoquinone and metastasis {#s0060}
===============================

Although the anti-metastatic effects of thymoquinone have been reported in numerous studies, the exact mechanism of action is not well understood. TQ showed remarkable suppression of metastatic phenotype and inverse transition from epithelial to mesenchymal portion in carcinoma of renal cells by modulating LKB1/AMPK signalling pathway. Enhanced expression of LKB1 and AMPK was observed in western blot results upon TQ treatment, also, upregulation in the phosphorylation of LKB1 and AMPK was shown in the 769-p cell line. A concentration-dependent enhancement in phosphorylation of LKB1 and AMPK was shown over 24 hr TQ treatment in 786-O cells. Upregulation in the expression of LKB1 enhanced the E-cadherin expression and reduces the Snail expression upon thymoquinone treatment in 786-O and 769-P cells ([@b0135], [@b0280]).

TQ efficiently reduced phosphorylation of IKK~α/β~ and NF-κB and reduced metastasis of CPT-11-R cells. Irinotecan resistant cells (CPT-11-R) LoVo colon cancer cell line upon TQ treatment showed the diminished activity of ERK1/2 and PI3K and increased activity of JNK and p38. NF-κB activation induces metastasis in CPT-11-R cells. Gelatin zymography, invasion assay, migration assay, and western blot showed dose-dependent reduction in the protein level of EMT marker, MMP-2 and MMP-9 upon TQ treatment. TQ treatment increases phosphorylation of JNK and p38, MAPKs, and reduction in the activity of ERK1/2 and PI3K ([@b0135], [@b0335]).

Ahmad et al., studied the anti-, metastasis effects of thymoquinone on human A375 and mouse B16F10 melanoma cell lines and tried to evaluate whether TQ inhibits metastasis of melanoma cells by targeting NLRP3 subunits of inflammasomes. Their results suggested that TQ may prove to be vital immunotherapeutic agent both alone and in combination therapy for melanoma in the control and prevention of metastasis ([@b0030]). In this study, 10 and 20 mg/kg body weight of thymoquinone significantly inhibited the metastatic tumor nodule formation in lungs, as compared to the vehicle control treated group.

Khan et al., in 2015 studied the effects of TQ on cancer metastasis inhibition by downregulation of TWIST1 expression and suggested that reduction of epithelial to mesenchymal transition is the key mechanism involved in that. The study was carried out in cancer cell line on EMT regulatory proteins and TQ was used in dose dependent manner to reduce the transcriptional activity of the TWIST1 promoter and its mRNA expression. The authors showed that TQ treatment reduced the expression of TWIST1 gene and inhibited cancer cell metastasis in cancer cells in xenograft tumors in mice ([@b0270]). The authors later reported that TQ leads to NF-κB inhibition, reduced expression of p38 MPAK through ROS generation and reduces the cancer cell metastasis by downregulation of EMT and inhibition of serine/threonine kinases Plk1 ([@b0275]).

Another study was performed to assess the anti-metastatic efficacy of thymoquinone on the pancreatic cancer in vitro and *in vivo*. Human pancreatic cancer simulating metastatic model was established where histologically intact pancreatic tumor tissue was orthotopically implanted into the pancreatic wall of nude mice. TQ treatment significantly decreased the tumor metastasis in comparison to normal control. It also led to the reduction in NF-κB and MMP9 expression in tumor tissues and established the anti-metastatic potential of TQ on pancreatic cancer ([@b0515]).

Mostofa et al., recently reviewed the potential of TQ as an adjuvant therapy in the treatment of cancer and provided evidences from preclinical studies and suggested that in addition to the cell death and tumor growth inhibitory potential, TQ also hinders in the many other diverse tumorigenic processes like angiogenesis, invasion and metastasis via metastatic signalling pathways. TQ treatment downregulates a number of signalling molecules like TGF-β, VEGF, FCF, EGF, metastatic factors, Nrf-2, STAT-3, that are responsible for and lead to transcriptional activation of genes involved in metastasis ([@b0330]).

11. Combinational therapy using thymoquinone {#s0065}
============================================

The insensitivity of gemcitabine in pancreatic cancer was overcome by pre-treatment of pancreatic cancer cell lines PANC-1, AsPC-1 and BxPC-3 cells with TQ. The synergistic effect shows potent antitumor effect via Notch1/PI3K/Akt/mTOR regulated signalling. Pre-treatment with TQ downregulates the anti-apoptotic Bcl-2, Bcl-xL, XIAP and upregulates pro-apoptotic molecules like caspase-3, caspase-9, Bax and enhances the release of cytochrome-c ([@b0335], [@b0210]).

Epithelial to mesenchymal transition (EMT) pertains to the progression and metastasis in cancer. The role of TQ and myrtucommulone-A (MC-A) in EMT showed negative regulation of EMT process via cancer cell signalling pathways. The effect of TQ and MC-A were compared with inhibitors, LY294002, SB431542 and U0126 in HTB-9 cells. Partial expression of phosphorylation of ERK ½ was showed by LY294002 while increase in AKT and β-catenin phosphorylation is a result of inhibition of ERK1/2. Activation of p38 MAPK, AKT and ERK1/2 shown by SB431542 and no stable pattern was seen in U0126 treatment. On the other hand, no inhibitors were able to match the pattern of effects of MC-A or TQ in HTB-9 or in MDB-MB-231 cells ([@b0215], [@b0210]).

The combined effect of TQ and resveratrol (RES) were shown on mice transplanted with breast cancer xenograft, and it caused a significant reduction of tumor size, induced apoptosis, geographic necrosis and reduced VEGF expression. The dose-dependent increment in response was seen upon TQ and RES in different cell lines. 15 uM RES with increasing TQ concentration showed a significant decrement in cell viability in EMT6/P cell line. The combination therapy of TQ and RES showed strongest antitumor activity as compared to TQ or RES treatment alone ([@b0045], [@b0055]).

TQ in combination with most active chemotherapeutic agent, cisplatin (CDDP) showed a remarkable effect in lung cancer. Nearly 90% inhibition of cell proliferation was recorded in NCI-H146 cell line of small cell lung carcinoma (SCLC) at the dose of 100 uM of TQ and 5 uM of CDDP upon 48 and 72 hr treatment. 20 mg/kg TQ and 2.5 mg/kg CDDP were combined to shrink the tumor volume by 79% ([@b0260], [@b0215]).

The cytotoxicity of TQ and CDDP were recorded in oral squamous cell carcinoma in UMSCC-14C and normal oral epithelial cells (OEC). Improvement in the cytotoxicity and reduction in IC~50~ was seen in UMSCC-14C cells upon 24, 48 and 72 hr incubation with a combination of TQ and CDDP. Combination of TQ and CDDP with 5 uM each, produces apoptosis in 99.1% of cells upon 24 hr incubation. TQ and CDDP combined treatment enhances P53 expression in UMSCC-14C and OEC cells by 3 and 5 times as compared to control. 5 and 6 times increment in the expression of caspase-9 was observed upon TQ and CDDP combined treatment as compared to control in UMSCC-14C and OEC cells ([@b0460], [@b0045]).

12. Chemopreventive and anticancer effects of thymoquinone {#s0070}
==========================================================

Cancer is a malignant growth or tumor resulting from an uncontrolled division of cells. It is estimated that around 9.6 million world population died due to cancer in 2018 (WHO 2018). It not only affects certain parts of the body but also spreads throughout the body and damages various vital organs. To treat cancer, already existing therapies like chemotherapy and radiation therapy have various side effects that are limiting its clinical use, so it becomes necessary to find new molecules without these limitations; hence, nowadays scientists are more focusing on natural products, which are safer as compare to other existing therapies. One such molecule is TQ which is obtained from N. *sativa*, however, very few authors have reviewed the chemopreventive and anticancer property of TQ in past ([@b0260]). Recently a lot more studies are going on the active constituents of N. *sativa* on various cancers such as lung cancer, colorectal cancer, prostate cancer, breast cancer, glioblastoma, and various other types of cancer **(**[Fig. 7](#f0035){ref-type="fig"}**)**. Acute and chronic toxicity studies have recently been performed to assess the safety of N. *sativa* oil and its primary active component, TQ, particularly when given via oral route. The above mentioned topic is aimed at summarizing some of the recent and significant work done by various scientists on the effects of TQ against various types of cancer ([@b0285]).Fig. 7Thymoquinone possess the potential in the prevention and treatment of different kinds of cancer.

12.1. Thymoquinone and lung cancer {#s0075}
----------------------------------

Lung cancer is the most common cancer worldwide, accounting for 1.3 million deaths annually. It has accounted for 1.76 million deaths worldwide in 2018 (WHO, 2018). Smoking is considered as the major cause of lung cancer; however, there are many other causes like passive smoking, lung disease, radon gas, familial predisposition, asbestos fibres and air pollution. Many researchers have studied the antitumor activity of TQ in vitro and *in vivo.* Recently scientists have shown cytotoxic effect of TQ on lung cancer cell line ([@b0460]). However, the detailed anticancer effects and its molecular mechanisms of TQ on lung cancer are yet to be elucidated. Scientists studied TQ effect on A549 lung cancer cell line to elucidate the cell proliferation, migration, and invasion as well as its underlying mechanisms of antimetastasis. The study showed that TQ is a potent anticancer drug in A549 cells, and showed selective cytotoxicity towards A549 cells. It also inhibits the proliferation rate of A549 cells in a dose/time-dependent manner. TQ downregulated the expression of proliferation marker PCNA and cyclin D1 in A549 cells after treatment with TQ. Hence, it was confirmed that TQ has a clear antiproliferative effect in vitro ([@b0340]).

It is also established that thymoquinone causes p53-independent apoptotic cell deaths by the stimulation of caspase-8 and caspase-9, followed by the downregulation of caspase-3 in the caspase ladder. Also caspase-8 activation increases the cytochrome-c discharge taking place from mitochondria to cytoplasm. It also controls the ratio of Bax/Bcl2 by upregulating the apoptosis favouring the Bax and down-regulating the apoptotic opposing Bcl2 proteins in p53-null HL-60 cell lines simultaneously with the process of apoptosis. Evaluating the anti-tumor effects of thymoquinone on A549 NSCLC cells treated with benzo (α) pyrene, Ulasli *et al* showed that thymoquinone exposure enhanced the Bax and reduced Bcl2 proteins, and subsequently enhanced the ratio of Bax/Bcl2. It also downregulated the cyclin D expression and upregulated the p21 expression, also it has also increased the expression of TRAIL receptor 1 and 2. The molecular outcomes finally result in a modulatory p53 level which affects the initiation cell cycle arrest in of G2/M phase and finally apoptosis ([@b0260]).

In the study of Benzo (α) pyrene induced animal model where animals showed considerably altered levels of heme indices with concomitantly decreased levels of membrane bound ATPases in the lung tissue and erythrocyte membrane, the TQ treated animals showed significant increase in the activities of membrane integrity enzymes and established the protective role of TQ in maintaining membrane-bound ATPases ([@b0340]).

12.2. Thymoquinone and colorectal cancer {#s0080}
----------------------------------------

Colorectal cancer mostly affects the colon and rectum which are the final parts of the gastrointestinal system. Colorectal cancer is one of the most universally diagnosed with gastrointestinal cancers and among the main causes of cancer-related death in western developed countries. Colorectal cancer is the third most common diagnosed cancer in both men and women. One in 22 men and one in 24 women will be diagnosed with colorectal cancer in their lifetime ([@b0455]). Scientists investigated the effect of TQ on colorectal cancer in vitro and *in vivo.* One of the researchers found that TQ significantly decreased the human LoVo colon cancer cell proliferation and also decreased the levels of p-PI3K, p-Akt, p-GSK3β, and β-catenin and thereby downregulated the downstream COX-2 expression which resulted in a reduction in PGE2 levels and the suppression of EP2 and EP4 activation. Further analysis showed that TQ treatment inhibited the nuclear translocation of β-catenin in LoVo cancer cells. TQ reduced the COX-2 expression at the transcriptional level and the reduction of COX-2 expression efficiently reduced LoVo cell migration. The results were further verified in an animal tumor xenograft model ([@b0200]). TQ, when given intraperitoneally reduced the formation of aberrant crypt foci and colon adenoma burden in Balb/c mice and also elicited a reduction in the incidence and multiplicity of colon tumors in Wistar rats both before and after treatment with 1,2-dimethylhydrazine. A decrease in the number of large polyps in the intestine of adenomatous polyposis coli (APC) mice was reported after oral feeding of TQ ([@b0290]).

12.3. Thymoquinone and prostate cancer {#s0085}
--------------------------------------

Prostate cancer is the cancer of prostate gland which is mainly present in men. It starts when cells in the prostate gland starts to grow uncontrollably. It makes fluid that is part of the semen. About 1 man in 9 is prone to prostate cancer during his lifetime. Among them, the older men aged above 65 are more prone to prostate cancer, and it is rare before the age of 40. The average age at the time of diagnosis is about 66 ([@b0455]). Several scientists have investigated the anticancer effect of TQ in prostate cancer both in vitro and *in vivo*. The authors have studied the TQ-induced growth inhibition in PC-3 and C4-2B prostate cancer cells, due to the generation of ROS. Results suggested that up-regulation of GADD45a and AIF and down-regulation of Bcl-2-related proteins might have a role in cell death by TQ in PC-3 cells. They also investigated that TQ-induced cell death in C4-2B cells is ROS dependent and not AR-dependent. TQ specifically inhibits proliferation and viability of cancerous cells but not the normal cells. Scientists observed that TQ stunted the growth of C4--2B derived tumors in nude mice in a xenograft prostate tumor model. This was associated with drastic downregulation of androgen receptor, transcription factor E2F-1, and cyclin A which was determined by Western blot analysis. Their findings clearly suggest that TQ may prove to be an effective agent in treating the hormone-sensitive, as well as hormone-refractory, prostate cancers with a reasonable degree of selectivity ([@b0095]).

12.4. Thymoquinone and breast cancer {#s0090}
------------------------------------

Breast cancer is the leading cause of death among different kinds of cancer. Antitumor activity of TQ in breast cancer was shown to be mediated through different modes of mechanisms, which includes induction of apoptosis, stimulation of immune system and inhibition of VEGF expression. RES showed the ability to enhance the anticancer activity of TQ through converging with the same pathways followed by TQ.

TQ reduced the proliferation rate of breast cancer cells and found to be significantly effective against tumor cell growth, invasion, and migration. It was shown that the TQ exhibits its anticancer effects through PPAR-γ pathway via binding to the receptors, and affecting their regulated gene products. It was also revealed that thymoquinone enhances the production of ROS, which ultimately leads to the phosphorylation of p38, resulting in the antiproliferative and pro-apoptotic efficacy of thymoquinone in breast cancer ([@b0505]).

In the xenograft mouse model, scientists explained the capability of thymoquinone to inhibit the growth of breast cancer, and the simultaneous treatment with doxorubicin showed significantly enhanced tumor inhibition. Moreover, thymoquinone also showed the increased expression of p-p38 protein in tumors, and a decrease in the XIAP, survivin, Bcl-xL, and Bcl-2 anti-apoptotic proteins ([@b0500]).

12.5. Thymoquinone and glioblastoma {#s0095}
-----------------------------------

Glioblastoma multiforme (GBM) is among the most devastating brain tumors with an average survival of not more than one year and comes with unique challenges to therapy because of its aggressive behaviour. It accounts for more than 40% of all malignant brain tumors and approximately 54.4% among all malignant gliomas with an average age at diagnosis being 64 years and more common in men rather than women ([@b0490]).

Thymoquinone also possess the capacity to induce concentration and exposure time-dependent apoptosis. The antiapoptotic efficacy of thymoquinone was established by the formation of DNA ladder, mitochondrial membrane potential loss in the cells undergoing apoptosis, however, this thymoquinone induced apoptosis largely depends upon activation of caspases since apoptosis was majorly curbed by the caspase inhibitor z-VAD-FMK in general. Therefore, these effects distinctly established that thymoquinone induced apoptosis could happen independently of p53- arbitrated cellular consequences. It is also established that around 50% of cancers in human entertain p53 mutations, the effects have significant entailments for establishing thymoquinone as a chemopreventive or chemotherapeutic agent ([@b0145]).

It has also been reported that TQ has the ability to interfere in normal cell cycle progression and thereby inhibits GBM growth. Several studies have reported that TQ can cause cell cycle arrest at different phases. TQ treatment can alter the expression of multiple cell cycle regulatory proteins, such as cyclin D1, cyclin E, and the CDK inhibitor p27, and induces apoptosis (accumulation of sub-G1 population) through caspase activation and PARP cleavage ([@b0145]).

12.6. Thymoquinone and other types of cancer {#s0100}
--------------------------------------------

The antitumor efficacy of thymoquinone appears to be significant both for tumor prevention and in treating various types of cancer. TQ exhibits selectivity to cancer cells, since normal cells, human pancreatic ductal epithelial cells (HPDE) and mouse keratinocytes are resistant to the apoptotic effects of TQ ([@b0095]). We briefly summarize below, the antitumor effects of TQ various other types of cancer.

### 12.6.1. Forestomach cancer {#s0105}

In the mice model, animals were protected against benzo (α) pyrene \[B(α)P\] induced forestomach cancer and chromosomal abnormalities in bone marrow cells. It was also established that daily consumption of the thymoquinone either before, during, or after the exposure to B(α)P decreased the occurrence of CAs damaged cells significantly as against the extremely mutagenic B(α)P solely, along with that tumor and heterogeneity was proved to be curbed in as much as 70 and 67% cases ([@b0085]).

### 12.6.2. Fibrosarcoma {#s0110}

The growth inhibitory and antitumor effects of TQ studied by Badary et al., in fibrosarcoma male Swiss albino mice induced by 20-methylcholanthrene. TQ was found to be significantly supressing the tumor incidences and tumor load (34% compared to 100% in normal control animals), as well as it also checked the onslaught of MC-induced fibrosarcoma cancers which is an indication of chemopreventive action against MC-induced fibrosarcomas ([@b0085]).

### 12.6.3. Ehrlich ascites carcinoma {#s0115}

Badary et al. found that thymoquinone enhanced the activity of cisplatin in Ehrlich ascites carcinoma-bearing animal model and concluded that thymoquinone (50 mg/l in ad libitum) when administered 5 days before and 5 days after single dose of cisplatin, reduced nephrotoxicity and potentiated the antitumor activity of cisplatin. Another study done by Badary in mice bearing EAC xenograft, revealed that TQ (10 mg/kg/day) in drinking water significantly potentiated the antitumor effect of Ifosfamide ([@b0085]).

13. Future perspective and conclusion {#s0120}
=====================================

The present day research has been focusing on novel therapeutic strategies which are preferably based upon natural resources and can provide some potent anti-cancer compounds eligible for application in the clinical settings. A great variety of natural compounds have been studies that possess a wide spectrum of pharmacological studies. A large number of studies have been undertaken on TQ and growing evidence of its application in an array of *in-vitro* and *in-vivo* designs. In the current manuscript, we documented from available literature that TQ possess great potential in acting as both a chemopreventive agent in cancer studies as well as, can also be applied in anti-tumor therapeutic paradigms. In addition, we have compiled a number of studies briefly describing chemistry and biosynthetic pathway of TQ synthesis, its occurrence in natural resources and a number of its pharmacological actions. Different toxicological and safety studies of TQ have also been taken into consideration in the present manuscript. Till date description of TQ has been quite broad in the available literature, in its capacity to be acting at a number of different steps in various disease processes including but not limited to inflammation, angiogenesis, apoptosis, cell cycle regulation, tumor metastasis etc. Additionally, the detailed role of TQ in its ability in targeting different kinds of cancer has been explained. Looking at the number of studies about TQ and the pace at which these studies have taken place and still growing it can be predicted that this compound will be explored and will exhibit a broad array of other further pharmacological actions as well. The authors came across diverse studies about the pharmacokinetics and pharmacodynamics of TQ, therefore a strong suggestion regarding the further exploration and compilation of pharmacokinetics and pharmacodynamics of TQ can be placed here. Also, a number of comprehensive dose-dependent toxicological studies of TQ need to be undertaken before it can be thoroughly applied in the clinical settings.
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